#02 with Dr. Kai Joachimsen, chief executive officer of the German Pharmaceutical Industry Association
In podcast episode #02 Orphan Drugs - more than a cost factor, Prof. Dr. Matthias P. Schönermark, and Dr. Kai Joachimsen shed light on the measures initiated to advance the development of orphan drugs over the last 20 years, the changes that the current political discussion could involve, and how the future of orphans is shaping up, especially in light of digitalization.
About the Profcast
Our SKC podcast series "The Profcast - rare diseases and their therapies" aims to address the special circumstances of patients with rare diseases, the associated medicine and the challenges for research, development, economics and reimbursement. For this purpose, Prof. Matthias P. Schönermark, M.D., Ph.D., managing director of SKC, speaks with patient representatives, payers, clinicians and scientists as well as industry representatives and also focuses on specific diseases. The word Profcast is a reference to professionals or professors, whom he welcomes as his guests.
The ambition behind this is to give an appropriate space to rare diseases and their treatment sine ira et studio. After all, the motto of the Rare Disease Day states it so aptly: "Rare is many". It is estimated that 4 million people in Germany and 300 million people worldwide are affected by a rare disease. In keeping with the Rare Disease Day, which traditionally takes place on the last day of February, the Profcast will always be published on the last day of a month.